Latest Conference Articles

Novel Combinations Under Study in Advanced RCC

Novel Combinations Under Study in Advanced RCC

April 12th 2021, 4:50pm

AACR Annual Meeting

The activity and safety of investigational combinations will be subject to study in patients with advanced clear cell renal cell carcinoma (ccRCC) as part of a phase 1b/2 umbrella platform trial.

AMG 176/Gilteritinib Combo Shows Preclinical Activity in FLT3-ITD+ AML

AMG 176/Gilteritinib Combo Shows Preclinical Activity in FLT3-ITD+ AML

April 12th 2021, 12:44pm

AACR Annual Meeting

The combination of the selective MCL-1 inhibitor AMG 176 plus gilteritinib was found to synergistically target preclinical models of FLT3 internal tandem duplication–mutated acute myeloid leukemia.

Neratinib Plus Fulvestrant Fails to Meet Efficacy Threshold in ER+ Metastatic Breast Cancer

Neratinib Plus Fulvestrant Fails to Meet Efficacy Threshold in ER+ Metastatic Breast Cancer

April 12th 2021, 12:16am

AACR Annual Meeting

Neratinib in combination with fulvestrant was active in heavily pretreated patients with estrogen receptor-positive, metastatic breast cancer, although the clinical benefit rate did not meet the predefined efficacy criteria.

Tislelizumab/Sitravatinib Shows Early Antitumor Activity, Safety in Platinum-Resistant Epithelial Ovarian Cancer

Tislelizumab/Sitravatinib Shows Early Antitumor Activity, Safety in Platinum-Resistant Epithelial Ovarian Cancer

April 11th 2021, 10:34pm

AACR Annual Meeting

The combination of tislelizumab and sitravatinib demonstrated early antitumor activity and a manageable safety profile in patients with recurrent platinum-resistant epithelial ovarian cancer and were naïve to PD-1/PD-L1 inhibition.

Parsaclisib/Ruxolitinib Improves SVR and Symptom Burden in Myelofibrosis

Parsaclisib/Ruxolitinib Improves SVR and Symptom Burden in Myelofibrosis

April 11th 2021, 7:27pm

AACR Annual Meeting

The combination of parsaclisib and ruxolitinib has resulted in the improvement of spleen volume reduction and symptom burden in patients with myelofibrosis who have previously experienced a suboptimal response to a standard dose of single-agent ruxolitinib.

Undetectable METex14 Following Savolitinib Is Associated with Higher PFS, OS in NSCLC

Undetectable METex14 Following Savolitinib Is Associated with Higher PFS, OS in NSCLC

April 11th 2021, 4:33pm

AACR Annual Meeting

Patients with non‒small cell lung cancer whose circulating tumor MET Exon 14 is undetectable following treatment with savolitinb are more likely to have positive outcomes.

Seribantumab Induces Tumor Regression in NRG1 Fusion+ GI Cancer Mouse Models

Seribantumab Induces Tumor Regression in NRG1 Fusion+ GI Cancer Mouse Models

April 11th 2021, 4:15pm

AACR Annual Meeting

Seribantumab demonstrated efficacy in reducing tumor growth in preclinical models of NRG1 fusion–positive gastrointestinal cancers, suggesting that the use of seribantumab as monotherapy could have clinical utility in treating patients with GI and other NRG1 fusion–driven cancers.

Pembrolizumab Demonstrates Robust Activity in Advanced and Recurrent/Metastatic CSCC

Pembrolizumab Demonstrates Robust Activity in Advanced and Recurrent/Metastatic CSCC

April 11th 2021, 4:00pm

AACR Annual Meeting

Single-agent pembrolizumab yielded robust antitumor activity in patients with locally advanced or recurrent/metastatic cutaneous squamous cell carcinoma.

Selpercatinib Demonstrates Favorable Safety Profile in RET-Altered Advanced Solid Tumors

Selpercatinib Demonstrates Favorable Safety Profile in RET-Altered Advanced Solid Tumors

April 11th 2021, 3:27pm

AACR Annual Meeting

Selpercatinib demonstrated a favorable safety profile, characterized by low-grade treatment-emergent adverse effects, manageable early onset toxicity, and low rates of treatment discontinuation, in patients with RET-altered advanced solid tumors.

TAS-117 Shows Limited Efficacy in Ovarian, Breast Tumors

TAS-117 Shows Limited Efficacy in Ovarian, Breast Tumors

April 11th 2021, 3:14pm

AACR Annual Meeting

Treatment with TAS-117, a highly potent and selective oral allosteric pan-v-akt murine thymoma viral oncogene homolog inhibitor, demonstrated some clinical efficacy in patients with ovarian cancer harboring PIK3CA E545K mutations and in those with breast cancer harboring PIK3CA H1047R and Akt1E17K mutations.

x